Cargando…
Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Amifostine (WR-2721), a thiol compound, has been shown to protect normal tissue from alkylating agents and cisplatin-induced toxicity without loss of anti-tumour effects. To confirm this result, we conducted a phase II randomised trial to determine if the addition of amifostine reduces the toxicity...
Autores principales: | Betticher, D. C., Anderson, H., Ranson, M., Meely, K., Oster, W., Thatcher, N. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034079/ https://www.ncbi.nlm.nih.gov/pubmed/8519676 |
Ejemplares similares
-
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
por: Korst, A. E., et al.
Publicado: (1997) -
Evaluation of protective effect of amifostine on dacarbazine induced genotoxicity
por: Etebari, M., et al.
Publicado: (2015) -
Protective effects of amifostine on ischemia-reperfusion injury of rat kidneys
por: Merter, Ayse Arducoglu, et al.
Publicado: (2015) -
The protective effect of amifostine on ultraviolet B-exposed xeroderma pigmentosum mice
por: Henry, SL, et al.
Publicado: (2010) -
Amifostine protects from the peripheral sensory neuropathy induced by oxaliplatin in mice
por: Pereira, A.F., et al.
Publicado: (2020)